Extract from the Register of European Patents

EP About this file: EP3218401

EP3218401 - PREDICTING RESPONSE TO A VEGF ANTAGONIST [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.01.2021
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  31.01.2020
FormerGrant of patent is intended
Status updated on  30.09.2019
FormerExamination is in progress
Status updated on  09.11.2018
FormerRequest for examination was made
Status updated on  18.08.2017
FormerThe international publication has been made
Status updated on  25.04.2017
Most recent event   Tooltip17.10.2025Change - lapse in a contracting state
New state(s): IS
published on 19.11.2025  [2025/47]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2017/38]
Inventor(s)01 / XIAO, Yuanyuan
1 Dna Way
South San Francisco, CA 94080-4990 / US
02 / BAIS, Carlos
1 Dna Way
South San Francisco, CA 94080-4990 / US
03 / CHOI, Younjeong
1 Dna Way
South San Francisco, CA 94080-4990 / US
04 / CONSALVO, Nicola, C.
Grenzacherstrasse 124
CH-4070 Basel / CH
 [2017/38]
Representative(s)Brodbeck, Michel, et al
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
[2017/38]
Application number, filing date15802244.209.11.2015
[2017/38]
WO2015US59733
Priority number, dateUS201462079787P14.11.2014         Original published format: US 201462079787 P
[2017/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016077227
Date:19.05.2016
Language:EN
[2016/20]
Type: A2 Application without search report 
No.:EP3218401
Date:20.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application.
[2017/38]
Type: B1 Patent specification 
No.:EP3218401
Date:04.03.2020
Language:EN
[2020/10]
Search report(s)International search report - published on:EP07.07.2016
ClassificationIPC:C07K16/22, A61K39/395, A61K31/282, A61K38/21, A61K45/06, A61K31/4745, A61K31/495, A61K31/513, A61K31/519, A61K31/704, A61K31/7068, A61K33/24, A61K31/555, A61K31/337, A61K39/00
[2019/41]
CPC:
C07K16/22 (EP,KR,US); A61K39/39558 (EP,CN,KR,US); A61K45/06 (EP,CN,KR,US);
A61K31/337 (EP,CN,KR,US); A61K31/4188 (KR); A61K31/4745 (EP,CN,US);
A61K31/495 (EP,US); A61K31/513 (EP,KR,US); A61K31/519 (EP,KR,US);
A61K31/555 (EP,US); A61K31/704 (EP,CN,US); A61K31/7068 (EP,KR,US);
A61K33/243 (EP,CN,KR,US); A61K38/21 (EP,KR,US); A61K38/212 (EP,US);
A61P1/04 (EP); A61P11/00 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P25/00 (EP); A61P35/00 (EP);
A61P43/00 (EP); C07K16/3069 (US); G01N33/57545 (US);
G01N33/577 (CN); A61K2039/505 (EP,US); A61K2300/00 (KR);
C07K2317/24 (US); C07K2317/76 (US); G01N2333/70596 (EP,CN,US);
G01N2333/71 (EP,CN,US); G01N2800/52 (EP,CN,US) (-)
C-Set:
A61K31/337, A61K2300/00 (US,CN,EP);
A61K31/4745, A61K2300/00 (US,CN,EP);
A61K31/495, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (EP,US);
A61K31/519, A61K2300/00 (EP,US);
A61K31/555, A61K2300/00 (US,EP);
A61K31/704, A61K2300/00 (US,CN,EP);
A61K31/7068, A61K2300/00 (US,EP);
A61K33/24, A61K2300/00 (US,EP);
A61K38/21, A61K2300/00 (US,EP);
A61K39/39558, A61K2300/00 (US,CN,EP)
(-)
Former IPC [2017/38]C07K16/22, A61K39/395, A61K31/282, A61K31/337, A61P35/00, A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/38]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VORHERSAGE DER REAKTION AUF EINEN VEGF-ANTAGONISTEN[2017/38]
English:PREDICTING RESPONSE TO A VEGF ANTAGONIST[2017/38]
French:PRÉDICTION DE RÉACTION À UN ANTAGONISTE DU VEGF[2017/38]
Entry into regional phase14.06.2017National basic fee paid 
14.06.2017Designation fee(s) paid 
14.06.2017Examination fee paid 
Examination procedure24.04.2017Date on which the examining division has become responsible
14.06.2017Examination requested  [2017/38]
19.12.2017Amendment by applicant (claims and/or description)
07.11.2018Despatch of a communication from the examining division (Time limit: M06)
07.05.2019Reply to a communication from the examining division
01.10.2019Communication of intention to grant the patent
24.01.2020Fee for grant paid
24.01.2020Fee for publishing/printing paid
24.01.2020Receipt of the translation of the claim(s)
Opposition(s)07.12.2020No opposition filed within time limit [2021/06]
Fees paidRenewal fee
08.11.2017Renewal fee patent year 03
08.11.2018Renewal fee patent year 04
14.11.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.11.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MK04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
BE30.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
[2025/47]
Former [2022/33]HU09.11.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MK04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
BE30.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2022/31]HU09.11.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MK04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2022/30]HU09.11.2015
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2022/27]HU09.11.2015
AT04.03.2020
CY04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2022/10]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2021/49]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
GB09.11.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2021/48]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
FR30.11.2020
LI30.11.2020
Former [2021/46]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
IE09.11.2020
LU09.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/37]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
LU09.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/33]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
LU09.11.2020
Former [2021/31]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/10]AT04.03.2020
CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
IT04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/08]CZ04.03.2020
DK04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/50]CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/49]CZ04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/48]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RO04.03.2020
RS04.03.2020
SE04.03.2020
SM04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/47]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/46]FI04.03.2020
HR04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/45]FI04.03.2020
HR04.03.2020
LV04.03.2020
NL04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
Former [2020/39]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
BG04.06.2020
NO04.06.2020
GR05.06.2020
Former [2020/38]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
NO04.06.2020
GR05.06.2020
Former [2020/37]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
SE04.03.2020
NO04.06.2020
Former [2020/35]FI04.03.2020
NO04.06.2020
Cited inInternational search[XI] WO2012118969  (US HEALTH et al.) [X] 1,25,26,60 * the whole document *[I] 2-24,27-42
 [A] US2011206662  (DUPONT JAKOB et al.) [A] 1-42,60 * the whole document *
 [XI] WO2011089101  (HOFFMANN LA ROCHE et al.) [X] 1,25,26,60 * the whole document *[I] 2-24,27-42
 [A] US2005276808  (CEDARBAUM JESSE M et al.) [A] 1-42,60 * the whole document *
 [A]   HAN E S ET AL: "Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 119, no. 3, 1 December 2010 (2010-12-01), pages 484 - 490, XP027471653, ISSN: 0090-8258, [retrieved on 20100925], DOI: 10.1016/J.YGYNO.2010.08.016 [A] 1-42,60 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2010.08.016
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.